Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy

28 Aug 2017

• By Michael Cipriano

US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.

Bad Apple — Will the bad apples make the public distrust the good ones?

US FDA is vowing a crackdown on "unscrupulous actors" in the regenerative medicine industry as part of a policy that could also benefit honest manufacturers.

Coming on the heels of a series of recent enforcement actions against stem cell centers in Florida and California, agency...